NASDAQ$LFST
LifeStance Health Group Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
LifeStance reported a 61% increase in fourth-quarter revenue and a 55% increase in clinician base.
LifeStance Health Group, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021, with a 61% increase in fourth-quarter revenue to $190.1 million and a 55% increase in the clinician base to 4,790 clinicians.
- Fourth quarter revenue increased 61% to $190.1 million.
- Clinician base increased 55% to 4,790 clinicians, including 415 net clinician adds in the fourth quarter.
- Net loss of $108.0 million in the fourth quarter.
- Adjusted EBITDA of positive $11.4 million in the fourth quarter.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$190M
Forward guidance
LifeStance is reiterating its preliminary outlook for 2022 revenue growth rate in the low 30s and Adjusted EBITDA dollar growth rate on pace with, or slightly greater than, revenue. The company expects full year revenue of $865 to $885 million, Center Margin of $240 to $255 million, and Adjusted EBITDA of $63 to $67 million.
Tailwinds
- Ability to execute on profitable growth strategy.
- Expand clinician population.
- Deliver best-in-class outpatient mental health services.
- Unique hybrid model provides competitive advantages.
- Operational flexibility.
Headwinds
- Plan to strategically moderate our de novo center openings in the second half of 2022 to improve profitability.
- Expect to open 80 to 90 de novo centers this year, compared to over 100 last year.
- Can flex the pace of physical location expansion based on current and projected patient and clinician demand for in-person visits.
- Mix of telehealth visits is currently over 80%.
- Omicron is expected to have an estimated revenue impact in the range of $3 to $7 million in the first quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro